AU3483900A - Non-stochastic generation of genetic vaccines and enzymes - Google Patents
Non-stochastic generation of genetic vaccines and enzymes Download PDFInfo
- Publication number
- AU3483900A AU3483900A AU34839/00A AU3483900A AU3483900A AU 3483900 A AU3483900 A AU 3483900A AU 34839/00 A AU34839/00 A AU 34839/00A AU 3483900 A AU3483900 A AU 3483900A AU 3483900 A AU3483900 A AU 3483900A
- Authority
- AU
- Australia
- Prior art keywords
- degenerate
- cassette
- mononucleotide
- polynucleotide
- optimized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000002068 genetic effect Effects 0.000 title claims description 200
- 229960005486 vaccine Drugs 0.000 title claims description 192
- 102000004190 Enzymes Human genes 0.000 title description 42
- 108090000790 Enzymes Proteins 0.000 title description 42
- 238000000034 method Methods 0.000 claims description 440
- 102000040430 polynucleotide Human genes 0.000 claims description 390
- 108091033319 polynucleotide Proteins 0.000 claims description 390
- 239000002157 polynucleotide Substances 0.000 claims description 390
- 150000007523 nucleic acids Chemical class 0.000 claims description 258
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 248
- 102000039446 nucleic acids Human genes 0.000 claims description 242
- 108020004707 nucleic acids Proteins 0.000 claims description 241
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 234
- 229920001184 polypeptide Polymers 0.000 claims description 219
- 210000004027 cell Anatomy 0.000 claims description 214
- 239000013598 vector Substances 0.000 claims description 172
- 108090000623 proteins and genes Proteins 0.000 claims description 169
- 108091007433 antigens Proteins 0.000 claims description 137
- 239000000427 antigen Substances 0.000 claims description 136
- 102000036639 antigens Human genes 0.000 claims description 134
- 230000028993 immune response Effects 0.000 claims description 120
- 102000004169 proteins and genes Human genes 0.000 claims description 84
- 150000001413 amino acids Chemical class 0.000 claims description 79
- 238000012216 screening Methods 0.000 claims description 71
- 230000035772 mutation Effects 0.000 claims description 65
- 239000002773 nucleotide Substances 0.000 claims description 61
- 230000014509 gene expression Effects 0.000 claims description 60
- 108090000695 Cytokines Proteins 0.000 claims description 58
- 238000002703 mutagenesis Methods 0.000 claims description 58
- 231100000350 mutagenesis Toxicity 0.000 claims description 58
- 102000004127 Cytokines Human genes 0.000 claims description 57
- 125000003729 nucleotide group Chemical group 0.000 claims description 57
- 238000001727 in vivo Methods 0.000 claims description 43
- 241000282414 Homo sapiens Species 0.000 claims description 41
- 102000005962 receptors Human genes 0.000 claims description 40
- 108020003175 receptors Proteins 0.000 claims description 40
- 230000000897 modulatory effect Effects 0.000 claims description 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
- 239000012634 fragment Substances 0.000 claims description 32
- 230000008569 process Effects 0.000 claims description 32
- 108020004705 Codon Proteins 0.000 claims description 31
- 241001465754 Metazoa Species 0.000 claims description 30
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 30
- 230000001965 increasing effect Effects 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 26
- 230000002519 immonomodulatory effect Effects 0.000 claims description 26
- 238000006467 substitution reaction Methods 0.000 claims description 26
- 108091034117 Oligonucleotide Proteins 0.000 claims description 24
- 241000124008 Mammalia Species 0.000 claims description 23
- 238000012360 testing method Methods 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 230000002163 immunogen Effects 0.000 claims description 21
- 230000005847 immunogenicity Effects 0.000 claims description 21
- 230000003505 mutagenic effect Effects 0.000 claims description 21
- 230000001939 inductive effect Effects 0.000 claims description 20
- 231100000219 mutagenic Toxicity 0.000 claims description 20
- 230000003321 amplification Effects 0.000 claims description 19
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 19
- 238000005457 optimization Methods 0.000 claims description 19
- 241001515965 unidentified phage Species 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 239000003446 ligand Substances 0.000 claims description 17
- 238000003259 recombinant expression Methods 0.000 claims description 17
- 230000000295 complement effect Effects 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 108091026890 Coding region Proteins 0.000 claims description 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 14
- 230000002829 reductive effect Effects 0.000 claims description 12
- 210000004962 mammalian cell Anatomy 0.000 claims description 11
- 239000003550 marker Substances 0.000 claims description 11
- 230000032258 transport Effects 0.000 claims description 11
- 239000005557 antagonist Substances 0.000 claims description 10
- 230000003247 decreasing effect Effects 0.000 claims description 10
- 230000004069 differentiation Effects 0.000 claims description 10
- 230000004927 fusion Effects 0.000 claims description 10
- 239000000556 agonist Substances 0.000 claims description 9
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 9
- 108010065805 Interleukin-12 Proteins 0.000 claims description 8
- 230000001413 cellular effect Effects 0.000 claims description 8
- 102000004388 Interleukin-4 Human genes 0.000 claims description 7
- 108090000978 Interleukin-4 Proteins 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- -1 IL-14 Proteins 0.000 claims description 6
- 102000003675 cytokine receptors Human genes 0.000 claims description 6
- 108010057085 cytokine receptors Proteins 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 230000010076 replication Effects 0.000 claims description 6
- 101150013553 CD40 gene Proteins 0.000 claims description 5
- 102000013462 Interleukin-12 Human genes 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 102000000588 Interleukin-2 Human genes 0.000 claims description 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 5
- 230000002950 deficient Effects 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 230000002194 synthesizing effect Effects 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 108090000176 Interleukin-13 Proteins 0.000 claims description 4
- 102000003816 Interleukin-13 Human genes 0.000 claims description 4
- 108010002616 Interleukin-5 Proteins 0.000 claims description 4
- 102000000743 Interleukin-5 Human genes 0.000 claims description 4
- 230000006052 T cell proliferation Effects 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 239000000430 cytokine receptor antagonist Substances 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 3
- 230000024245 cell differentiation Effects 0.000 claims description 3
- 230000007423 decrease Effects 0.000 claims description 3
- 230000008488 polyadenylation Effects 0.000 claims description 3
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 229940117681 interleukin-12 Drugs 0.000 claims description 2
- 230000029069 type 2 immune response Effects 0.000 claims description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 claims 4
- 102000009410 Chemokine receptor Human genes 0.000 claims 2
- 108050000299 Chemokine receptor Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 108090000174 Interleukin-10 Proteins 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 238000000137 annealing Methods 0.000 claims 2
- 108090000237 interleukin-24 Proteins 0.000 claims 2
- 102000003898 interleukin-24 Human genes 0.000 claims 2
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 241000206602 Eukaryota Species 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102000004551 Interleukin-10 Receptors Human genes 0.000 claims 1
- 108010017550 Interleukin-10 Receptors Proteins 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 102000049772 Interleukin-16 Human genes 0.000 claims 1
- 101800003050 Interleukin-16 Proteins 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 102000013691 Interleukin-17 Human genes 0.000 claims 1
- 102000003810 Interleukin-18 Human genes 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 241000209510 Liliopsida Species 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 230000029662 T-helper 1 type immune response Effects 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 241001233957 eudicotyledons Species 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 claims 1
- 108091005485 macrophage scavenger receptors Proteins 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 102000014452 scavenger receptors Human genes 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 79
- 108020004414 DNA Proteins 0.000 description 74
- 235000001014 amino acid Nutrition 0.000 description 62
- 238000009739 binding Methods 0.000 description 58
- 230000027455 binding Effects 0.000 description 57
- 229940024606 amino acid Drugs 0.000 description 53
- 241000894007 species Species 0.000 description 43
- 229940088598 enzyme Drugs 0.000 description 41
- 238000000338 in vitro Methods 0.000 description 35
- 239000000047 product Substances 0.000 description 35
- 108091028043 Nucleic acid sequence Proteins 0.000 description 33
- 230000001976 improved effect Effects 0.000 description 30
- 230000001717 pathogenic effect Effects 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 29
- 244000052769 pathogen Species 0.000 description 29
- 210000000612 antigen-presenting cell Anatomy 0.000 description 28
- 239000004698 Polyethylene Substances 0.000 description 27
- 238000003786 synthesis reaction Methods 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 26
- 239000003795 chemical substances by application Substances 0.000 description 25
- 230000000670 limiting effect Effects 0.000 description 24
- 239000003981 vehicle Substances 0.000 description 24
- 238000003752 polymerase chain reaction Methods 0.000 description 21
- 239000000203 mixture Substances 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 238000013459 approach Methods 0.000 description 19
- 238000010168 coupling process Methods 0.000 description 19
- 238000005859 coupling reaction Methods 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 238000009396 hybridization Methods 0.000 description 19
- 230000000890 antigenic effect Effects 0.000 description 18
- 230000008878 coupling Effects 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 238000004422 calculation algorithm Methods 0.000 description 17
- 230000003053 immunization Effects 0.000 description 17
- 238000002649 immunization Methods 0.000 description 17
- 229940124856 vaccine component Drugs 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 230000006798 recombination Effects 0.000 description 13
- 238000005215 recombination Methods 0.000 description 13
- 238000007792 addition Methods 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 238000011161 development Methods 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 201000004792 malaria Diseases 0.000 description 12
- 244000045947 parasite Species 0.000 description 12
- 239000013615 primer Substances 0.000 description 12
- 230000009870 specific binding Effects 0.000 description 12
- 241000223960 Plasmodium falciparum Species 0.000 description 11
- 238000001994 activation Methods 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 230000004913 activation Effects 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 108020004638 Circular DNA Proteins 0.000 description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 101710198693 Invasin Proteins 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000002741 site-directed mutagenesis Methods 0.000 description 9
- 108010011619 6-Phytase Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 229940085127 phytase Drugs 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 7
- 108091007494 Nucleic acid- binding domains Proteins 0.000 description 7
- 108700008625 Reporter Genes Proteins 0.000 description 7
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 230000009897 systematic effect Effects 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 102000019034 Chemokines Human genes 0.000 description 6
- 108010012236 Chemokines Proteins 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 238000011239 genetic vaccination Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 5
- 108091092195 Intron Proteins 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108091005461 Nucleic proteins Proteins 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 230000030741 antigen processing and presentation Effects 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000002443 helper t lymphocyte Anatomy 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 230000003308 immunostimulating effect Effects 0.000 description 5
- 229960000310 isoleucine Drugs 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000004962 physiological condition Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 239000004474 valine Substances 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- 108010045374 CD36 Antigens Proteins 0.000 description 4
- 102000053028 CD36 Antigens Human genes 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 101000723939 Mus musculus Transcription factor HIVEP3 Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 4
- 230000017274 T cell anergy Effects 0.000 description 4
- 235000008206 alpha-amino acids Nutrition 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000000139 costimulatory effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000010502 episomal replication Effects 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 239000002955 immunomodulating agent Substances 0.000 description 4
- 229940121354 immunomodulator Drugs 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000000663 muscle cell Anatomy 0.000 description 4
- 239000003471 mutagenic agent Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000006337 proteolytic cleavage Effects 0.000 description 4
- 238000002708 random mutagenesis Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 4
- 230000009919 sequestration Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000003637 steroidlike Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- 241000282708 Aotus <primate> Species 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 102000043131 MHC class II family Human genes 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 241000224024 Plasmodium chabaudi Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
- 102000002938 Thrombospondin Human genes 0.000 description 3
- 108060008245 Thrombospondin Proteins 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 150000001371 alpha-amino acids Chemical class 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000002584 immunomodulator Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000002934 lysing effect Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 102000044158 nucleic acid binding protein Human genes 0.000 description 3
- 108700020942 nucleic acid binding protein Proteins 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 230000003334 potential effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 2
- 101710096438 DNA-binding protein Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 108010024212 E-Selectin Proteins 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101710160107 Outer membrane protein A Proteins 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000027645 antigenic variation Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000012219 cassette mutagenesis Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003617 erythrocyte membrane Anatomy 0.000 description 2
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000001821 langerhans cell Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000033607 mismatch repair Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 210000002729 polyribosome Anatomy 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000014639 sexual reproduction Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 244000052613 viral pathogen Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- AWNBSWDIOCXWJW-WTOYTKOKSA-N (2r)-n-[(2s)-1-[[(2s)-1-(2-aminoethylamino)-1-oxopropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n'-hydroxy-2-(2-methylpropyl)butanediamide Chemical compound C1=CC=CC2=CC(C[C@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)C(=O)N[C@@H](C)C(=O)NCCN)=CC=C21 AWNBSWDIOCXWJW-WTOYTKOKSA-N 0.000 description 1
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
- BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101100152304 Caenorhabditis elegans tap-1 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 102000015689 E-Selectin Human genes 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101001082397 Human adenovirus B serotype 3 Hexon-associated protein Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000222732 Leishmania major Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 102000011202 Member 2 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 240000009188 Phyllostachys vivax Species 0.000 description 1
- 108010088113 Plasmodium falciparum erythrocyte membrane protein 1 Proteins 0.000 description 1
- 241000223819 Plasmodium fragile Species 0.000 description 1
- 241000223801 Plasmodium knowlesi Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101001120093 Pseudoalteromonas phage PM2 Protein P8 Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101710086015 RNA ligase Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101800001707 Spacer peptide Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
- 102100028082 Tapasin Human genes 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 229960004784 allergens Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 229940076005 apoptosis modulator Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000009614 chemical analysis method Methods 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010960 commercial process Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- MKZGVLPHKXXSSG-UHFFFAOYSA-N ethyl n-[4-[benzyl(2-phenylethyl)amino]-2-[4-(trifluoromethyl)phenyl]-1h-imidazo[4,5-c]pyridin-6-yl]carbamate Chemical compound N=1C(NC(=O)OCC)=CC=2NC(C=3C=CC(=CC=3)C(F)(F)F)=NC=2C=1N(CC=1C=CC=CC=1)CCC1=CC=CC=C1 MKZGVLPHKXXSSG-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003126 m-cell Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 208000037941 meningococcal disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 230000034778 micropinocytosis Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 101150049514 mutL gene Proteins 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 108010088142 pfalhesin Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000036178 pleiotropy Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 101150056906 recJ gene Proteins 0.000 description 1
- 230000012121 regulation of immune response Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000032537 response to toxin Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 101150072534 sbcB gene Proteins 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000003373 small molecule array Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 108010059434 tapasin Proteins 0.000 description 1
- 230000001551 toxigenic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000003812 trophozoite Anatomy 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 101150115617 umuC gene Proteins 0.000 description 1
- 101150046028 umuD gene Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 101150100239 vsr gene Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/11—Exodeoxyribonucleases producing 5'-phosphomonoesters (3.1.11)
- C12Y301/11002—Exodeoxyribonuclease III (3.1.11.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Ecology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2005201125A AU2005201125B2 (en) | 1999-02-04 | 2005-03-15 | Non-stochastic generation of genetic vaccines and enzymes |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/246,178 US6171820B1 (en) | 1995-12-07 | 1999-02-04 | Saturation mutagenesis in directed evolution |
| US09246178 | 1999-02-04 | ||
| PCT/US2000/003086 WO2000046344A2 (en) | 1999-02-04 | 2000-02-04 | Non-stochastic generation of genetic vaccines and enzymes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005201125A Division AU2005201125B2 (en) | 1999-02-04 | 2005-03-15 | Non-stochastic generation of genetic vaccines and enzymes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU3483900A true AU3483900A (en) | 2000-08-25 |
Family
ID=22929614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU34839/00A Abandoned AU3483900A (en) | 1999-02-04 | 2000-02-04 | Non-stochastic generation of genetic vaccines and enzymes |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6171820B1 (https=) |
| JP (2) | JP2003524392A (https=) |
| AU (1) | AU3483900A (https=) |
| CA (1) | CA2325351C (https=) |
| WO (1) | WO2000046344A2 (https=) |
Families Citing this family (175)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US6165793A (en) * | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6395547B1 (en) | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6995017B1 (en) | 1994-02-17 | 2006-02-07 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5830696A (en) | 1996-12-05 | 1998-11-03 | Diversa Corporation | Directed evolution of thermophilic enzymes |
| US6939689B2 (en) | 1995-12-07 | 2005-09-06 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
| US6764835B2 (en) * | 1995-12-07 | 2004-07-20 | Diversa Corporation | Saturation mutageneis in directed evolution |
| US6740506B2 (en) * | 1995-12-07 | 2004-05-25 | Diversa Corporation | End selection in directed evolution |
| US20030219752A1 (en) * | 1995-12-07 | 2003-11-27 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
| US6713279B1 (en) | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
| US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
| US6506602B1 (en) | 1996-03-25 | 2003-01-14 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US20070009930A1 (en) * | 1996-12-18 | 2007-01-11 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| KR100570935B1 (ko) | 1997-01-17 | 2006-04-13 | 맥시겐, 인크. | 반복적 서열 재조합에 의한 전세포 및 유기체의 개량 방법 |
| US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| US7148054B2 (en) | 1997-01-17 | 2006-12-12 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| US6159688A (en) | 1997-03-18 | 2000-12-12 | Novo Nordisk A/S | Methods of producing polynucleotide variants |
| EP1025217B1 (en) | 1997-10-24 | 2006-10-04 | Invitrogen Corporation | Recombinational cloning using nucleic acids having recombination sites |
| US6537746B2 (en) | 1997-12-08 | 2003-03-25 | Maxygen, Inc. | Method for creating polynucleotide and polypeptide sequences |
| US7390619B1 (en) * | 1998-02-11 | 2008-06-24 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
| US6541011B2 (en) | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| IL139093A0 (en) | 1998-05-01 | 2001-11-25 | Maxygen Inc | Optimization of pest resistance genes using dna shuffling |
| US7153655B2 (en) * | 1998-06-16 | 2006-12-26 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence |
| US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
| US6991922B2 (en) * | 1998-08-12 | 2006-01-31 | Proteus S.A. | Process for in vitro creation of recombinant polynucleotide sequences by oriented ligation |
| US20030104417A1 (en) * | 1998-08-12 | 2003-06-05 | Proteus S.A. | Template-mediated, ligation-oriented method of nonrandomly shuffling polynucleotides |
| US6951719B1 (en) * | 1999-08-11 | 2005-10-04 | Proteus S.A. | Process for obtaining recombined nucleotide sequences in vitro, libraries of sequences and sequences thus obtained |
| US20030092023A1 (en) * | 1998-08-12 | 2003-05-15 | Daniel Dupret | Method of shuffling polynucleotides using templates |
| CA2360011A1 (en) * | 1999-01-05 | 2000-07-13 | Trustees Of Boston University | Ordered gene assembly |
| US20040005673A1 (en) * | 2001-06-29 | 2004-01-08 | Kevin Jarrell | System for manipulating nucleic acids |
| US6436675B1 (en) | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
| EP1151409A1 (en) * | 1999-01-18 | 2001-11-07 | Maxygen, Inc. | Methods of populating data stuctures for use in evolutionary simulations |
| US20070065838A1 (en) * | 1999-01-19 | 2007-03-22 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US20090130718A1 (en) * | 1999-02-04 | 2009-05-21 | Diversa Corporation | Gene site saturation mutagenesis |
| JP3399518B2 (ja) * | 1999-03-03 | 2003-04-21 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 半導体構造およびその製造方法 |
| AU3391900A (en) | 1999-03-05 | 2000-09-21 | Maxygen, Inc. | Encryption of traits using split gene sequences |
| US20040002474A1 (en) * | 1999-10-07 | 2004-01-01 | Maxygen Inc. | IFN-alpha homologues |
| AU1456101A (en) | 1999-11-03 | 2001-05-14 | Maxygen, Inc. | Antibody diversity generation |
| US7115712B1 (en) * | 1999-12-02 | 2006-10-03 | Maxygen, Inc. | Cytokine polypeptides |
| IL150291A0 (en) * | 2000-01-11 | 2002-12-01 | Maxygen Inc | Integrated systems and methods for diversity generation and screening |
| AU2001241939A1 (en) * | 2000-02-28 | 2001-09-12 | Maxygen, Inc. | Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation |
| US20010049104A1 (en) * | 2000-03-24 | 2001-12-06 | Stemmer Willem P.C. | Methods for modulating cellular and organismal phenotypes |
| US6479262B1 (en) | 2000-05-16 | 2002-11-12 | Hercules, Incorporated | Solid phase enzymatic assembly of polynucleotides |
| EP1360290A2 (en) * | 2000-06-23 | 2003-11-12 | Maxygen, Inc. | Co-stimulatory molecules |
| WO2002000897A2 (en) * | 2000-06-23 | 2002-01-03 | Maxygen, Inc. | Novel chimeric promoters |
| AU2001271912A1 (en) * | 2000-07-07 | 2002-01-21 | Maxygen, Inc. | Molecular breeding of transposable elements |
| US6858422B2 (en) * | 2000-07-13 | 2005-02-22 | Codexis, Inc. | Lipase genes |
| US7435562B2 (en) * | 2000-07-21 | 2008-10-14 | Modular Genetics, Inc. | Modular vector systems |
| AU2001277014A1 (en) * | 2000-07-21 | 2002-02-05 | Trustees Of Boston University | Modular vector systems |
| US7198924B2 (en) * | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
| US20020132308A1 (en) * | 2000-08-24 | 2002-09-19 | Mpep @ Page 300-M | Novel constructs and their use in metabolic pathway engineering |
| JP2002083691A (ja) * | 2000-09-06 | 2002-03-22 | Sharp Corp | アクティブマトリックス駆動型有機ｌｅｄ表示装置及びその製造方法 |
| WO2005012515A2 (en) | 2003-04-29 | 2005-02-10 | Pioneer Hi-Bred International, Inc. | Novel glyphosate-n-acetyltransferase (gat) genes |
| US20040006778A1 (en) * | 2002-02-15 | 2004-01-08 | Diversa Corporation | Chimeric cannulae proteins, nucleic acids encoding them and methods for making and using them |
| US6958213B2 (en) | 2000-12-12 | 2005-10-25 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function |
| US20020086292A1 (en) | 2000-12-22 | 2002-07-04 | Shigeaki Harayama | Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules |
| CA2436214C (en) * | 2001-02-02 | 2012-12-04 | Large Scale Biology Corporation | A method of increasing complementarity in a heteroduplex polynucleotide |
| US20030036854A1 (en) * | 2001-02-06 | 2003-02-20 | The Penn State Research Foundation | Apparatus and method for designing proteins and protein libraries |
| EP1277835A1 (en) * | 2001-07-19 | 2003-01-22 | Libragen | Methods of creating genetic diversity |
| US7647184B2 (en) * | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
| US20030129203A1 (en) * | 2001-08-27 | 2003-07-10 | Nautilus Biotech S.A. | Mutant recombinant adeno-associated viruses |
| ES2411007T3 (es) | 2001-10-10 | 2013-07-04 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
| CA2468710A1 (en) * | 2001-12-03 | 2003-06-12 | Diversa Corporation | Chromosomal saturation mutagenesis |
| TWI262083B (en) * | 2001-12-28 | 2006-09-21 | Syngenta Participations Ag | Microbially-expressed thermotolerant phytase for animal feed |
| US20040009498A1 (en) * | 2002-01-14 | 2004-01-15 | Diversa Corporation | Chimeric antigen binding molecules and methods for making and using them |
| AU2002306484A1 (en) | 2002-02-13 | 2003-09-04 | Dow Global Technologies Inc. | Over-expression of extremozyme genes in pseudomonads and closely related bacteria |
| US20030166010A1 (en) * | 2002-02-25 | 2003-09-04 | Affholter Joseph A. | Custom ligand design for biomolecular filtration and purification for bioseperation |
| US20030224404A1 (en) * | 2002-02-25 | 2003-12-04 | Manuel Vega | High throughput directed evolution of nucleic acids by rational mutagenesis |
| JP5319865B2 (ja) | 2002-03-01 | 2013-10-16 | コデクシス メイフラワー ホールディングス， エルエルシー | 機能的生体分子を同定する方法、システム、およびソフトウェア |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20030199068A1 (en) * | 2002-03-05 | 2003-10-23 | Bott Richard R. | High throughput mutagenesis screening method |
| US20030171543A1 (en) * | 2002-03-05 | 2003-09-11 | Bott Richard R. | High throughput mutagenesis screening method |
| EP1488335A4 (en) | 2002-03-09 | 2006-11-15 | Maxygen Inc | OPTIMIZING CROSSOVER POINTS FOR THE ADJUSTED EVOLUTION |
| US7226771B2 (en) | 2002-04-19 | 2007-06-05 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
| PT1497418E (pt) | 2002-04-19 | 2013-01-25 | Dsm Ip Assets Bv | Fosfolípases, ácidos nucleicos que as codificam e métodos para as preparar e utilizar |
| DK1504098T4 (da) * | 2002-05-17 | 2011-05-23 | Alligator Bioscience Ab | Fremgangsmåde til molekyulær udvikling in vitro af proteinfunktion |
| JP2005532829A (ja) * | 2002-07-18 | 2005-11-04 | インヴィトロジェン コーポレーション | 組換え部位を含むウイルスベクター |
| US20060155153A1 (en) * | 2002-08-02 | 2006-07-13 | Sergey Selifonov | Methods for making(-)-menthol and oxygenated menthane compounds |
| BR0313281A (pt) | 2002-08-06 | 2007-07-24 | Verdia Inc | variantes de ap1 amina oxidase |
| US20050202438A1 (en) * | 2002-09-09 | 2005-09-15 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
| US20060020396A1 (en) * | 2002-09-09 | 2006-01-26 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
| DE60332358D1 (de) * | 2002-09-09 | 2010-06-10 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| EP1553975B8 (en) | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| CA3007908A1 (en) | 2003-03-07 | 2005-04-14 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
| PL1615945T3 (pl) | 2003-04-09 | 2012-03-30 | Ratiopharm Gmbh | Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami |
| WO2005028615A2 (en) * | 2003-06-26 | 2005-03-31 | Invitrogen Corporation | Methods and compositions for detecting promoter activity and expressing fusion proteins |
| WO2005049831A1 (en) * | 2003-11-20 | 2005-06-02 | Agency For Science Technology And Research | Method |
| WO2005054438A2 (en) * | 2003-12-01 | 2005-06-16 | Invitrogen Corporation | Nucleic acid molecules containing recombination sites and methods of using the same |
| US7204950B2 (en) * | 2003-12-19 | 2007-04-17 | Pepsico, Inc. | Dispensing package |
| KR101225918B1 (ko) | 2004-02-25 | 2013-01-24 | 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 | 신규한 바실루스 투링기엔시스 결정 폴리펩티드,폴리뉴클레오티드, 및 이의 조성물 |
| CN101023181A (zh) | 2004-05-21 | 2007-08-22 | 加利福尼亚大学董事会 | 提高类异戊二烯化合物的产生的方法 |
| ATE482281T1 (de) | 2004-06-09 | 2010-10-15 | Pioneer Hi Bred Int | Plastiden transit peptide |
| CN101048506B (zh) | 2004-10-27 | 2013-06-26 | 斯克利普斯研究院 | 体内掺入非天然氨基酸的正交翻译组分 |
| US7998930B2 (en) * | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
| WO2006053131A1 (en) * | 2004-11-11 | 2006-05-18 | Modular Genetics, Inc. | Ladder assembly and system for generating diversity |
| EP2886658A1 (en) | 2005-03-10 | 2015-06-24 | BASF Enzymes LLC | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
| CA2611859C (en) | 2005-03-15 | 2015-03-31 | Verenium Corporation | Cellulases, nucleic acids encoding them and methods for making and using them |
| US20070184472A1 (en) * | 2005-06-08 | 2007-08-09 | Toagosei Co., Ltd | Method of purifying environmental dna and method of efficiently screening for protein-encoding gene from environmental dna |
| HUE029021T2 (en) | 2005-06-21 | 2017-02-28 | Xoma (Us) Llc | IL-1beta-binding antibodies and fragments thereof |
| GB2432366B (en) * | 2005-11-19 | 2007-11-21 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
| EP1987142A4 (en) | 2006-02-02 | 2009-07-15 | Verenium Corp | ESTERASES AND ASSOCIATED NUCLEIC ACIDS AND METHODS |
| NZ595497A (en) | 2006-02-10 | 2013-09-27 | Verenium Corp | Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them |
| TR201809912T4 (tr) | 2006-02-14 | 2018-07-23 | Bp Corp North America Inc | Ksilanazlar, bunları kodlayan nükleik asitler ve bunları yapmak ve kullanmak için yöntemler. |
| AU2007223086B2 (en) | 2006-03-07 | 2013-09-26 | Basf Enzymes Llc | Aldolases, nucleic acids encoding them and methods for making and using them |
| MX2008011477A (es) | 2006-03-07 | 2008-09-23 | Cargill Inc | Aldolasas, acidos nucleicos que las codifican y metodos para hacerlas y usarlas. |
| WO2007134327A2 (en) | 2006-05-15 | 2007-11-22 | Sea Lane Biotechnologies, Llc. | Neutralizing antibodies to influenza viruses |
| US20070294785A1 (en) * | 2006-06-13 | 2007-12-20 | Athenix Corporation | Methods for generating genetic diversity by permutational mutagenesis |
| DK2069389T3 (en) | 2006-08-04 | 2015-01-12 | Bp Corp North America Inc | Glucanases, nucleic acids encoding them, and processes for their preparation and use |
| ES2531135T3 (es) | 2006-09-21 | 2015-03-11 | Basf Enzymes Llc | Fitasas, ácidos nucleicos que las codifican y métodos para su producción y uso |
| EP2057274B1 (en) | 2006-09-21 | 2013-12-11 | DSM IP Assets B.V. | Phospholipases, nucleic acids encoding them and methods for making and using them |
| EP2121756A4 (en) | 2006-12-20 | 2011-08-31 | Mmrglobal Inc | ANTIBODIES AND PROCESS FOR THEIR PREPARATION AND USE |
| PL2479267T3 (pl) | 2006-12-21 | 2017-06-30 | Basf Enzymes Llc | Amylazy i glukoamylazy, kwasy nukleinowe kodujące te związki oraz sposoby wytwarzania tych związków oraz stosowania ich |
| NZ598285A (en) | 2007-01-30 | 2013-10-25 | Syngenta Participations Ag | Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them |
| KR101621100B1 (ko) | 2007-03-30 | 2016-05-13 | 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 | 백신에 유용한 약독화 바이러스 |
| CA2693102C (en) | 2007-07-31 | 2020-03-10 | Verenium Corporation | Tailored multi-site combinatorial assembly |
| BRPI0817811A2 (pt) | 2007-10-03 | 2014-10-14 | Verenium Corp | Xilanases, ácidos nucleicos que codificam as mesmas e métodos para fabricação e uso das mesmas. |
| ES2647767T3 (es) | 2007-12-03 | 2017-12-26 | Syngenta Participations Ag | Generación por ingeniería genética de proteínas enzimáticamente susceptibles |
| AU2008347218B2 (en) * | 2007-12-31 | 2015-02-05 | Xoma Technology Ltd. | Methods and materials for targeted mutagenesis |
| CN104651381A (zh) | 2008-01-03 | 2015-05-27 | 巴斯夫酶有限责任公司 | 转移酶和氧化还原酶、编码它们的核酸以及其制备和应用方法 |
| WO2009088753A1 (en) | 2008-01-03 | 2009-07-16 | Verenium Corporation | Isomerases, nucleic acids encoding them and methods for making and using them |
| EP2247309A4 (en) * | 2008-01-28 | 2013-10-16 | Tapimmune Inc | TAPASINE REINFORCEMENT FOR AN IMPROVED IMMUNE RESPONSE |
| JP2011516423A (ja) | 2008-03-28 | 2011-05-26 | シー レーン バイオテクノロジーズ， エルエルシー | ウイルス抗原に対する中和分子 |
| US20110124520A1 (en) * | 2008-05-30 | 2011-05-26 | Massachuesetts Institute Of Technology | Compositions and Methods for Spatial Separation and Screening of Cells |
| US20090312196A1 (en) * | 2008-06-13 | 2009-12-17 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
| US8383346B2 (en) * | 2008-06-13 | 2013-02-26 | Codexis, Inc. | Combined automated parallel synthesis of polynucleotide variants |
| US8153391B2 (en) | 2008-08-29 | 2012-04-10 | Bunge Oils, Inc. | Hydrolases, nucleic acids encoding them and methods for making and using them |
| US8357503B2 (en) | 2008-08-29 | 2013-01-22 | Bunge Oils, Inc. | Hydrolases, nucleic acids encoding them and methods for making and using them |
| US8198062B2 (en) | 2008-08-29 | 2012-06-12 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
| BRPI0917075B1 (pt) * | 2008-12-02 | 2019-11-12 | Consejo Nacional De Investigaciones Cientificas Y Tecn | protozoário parasita giardia modificado e vacina contra infecções produzidas por protozoários |
| US20120190071A1 (en) | 2009-05-12 | 2012-07-26 | Council Of Scientific & Industrial Research | Lipa and its variant useful for biofuel production |
| NZ596459A (en) | 2009-05-21 | 2013-11-29 | Verenium Corp | Phytases, nucleic acids encoding them and methods for making and using them |
| SG10201700096VA (en) | 2009-07-17 | 2017-02-27 | Bioatla Llc | Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts |
| UA109884C2 (uk) | 2009-10-16 | 2015-10-26 | Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування | |
| UA111708C2 (uk) | 2009-10-16 | 2016-06-10 | Бандж Ойлз, Інк. | Спосіб рафінування олії |
| WO2011109726A2 (en) * | 2010-03-05 | 2011-09-09 | Bioatla Llc | Homologous multi-specific antibodies |
| ES2741175T3 (es) | 2010-07-16 | 2020-02-10 | Bioatla Llc | Nuevos métodos de evolución de proteínas |
| BR112013003135A2 (pt) | 2010-08-13 | 2017-11-07 | Pioneer Hi Bred Int | polinucletídeo e polipeptídeo isolado ou recombinante, construto de ácido nucleico, célula, planta, explante vegetal, semente transgênica, método para produção de célula vegetal para controle de plantas daninhas e para detecção de um polipeptídeo hppd e um polinucleotídeo. |
| US9096871B2 (en) | 2010-10-06 | 2015-08-04 | Bp Corporation North America Inc. | Variant CBH I polypeptides with reduced product inhibition |
| EP2640831A1 (en) | 2010-11-17 | 2013-09-25 | Sea Lane Biotechnologies,llc. | Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody |
| US20140182011A1 (en) | 2011-11-03 | 2014-06-26 | The University Of Hong Kong | Methods Using Acyl-Coenzyme A-Binding Proteins to Enchance Drought Tolerance in Genetically Modified Plants |
| BR112014022943A2 (pt) | 2012-03-16 | 2017-07-18 | Bp Corp North America Inc | polipeptídeos que possuem atividade de endoglicanase |
| US20150184173A1 (en) | 2012-05-04 | 2015-07-02 | E I Du Pont De Nemours And Company | Compositions and methods comprising sequences having meganuclease activity |
| AU2013259276B2 (en) | 2012-05-10 | 2018-03-22 | Bioatla Llc | Multi-specific monoclonal antibodies |
| IN2015DN02049A (https=) | 2012-08-16 | 2015-08-14 | Bangladesh Jute Res Inst | |
| CN104870640A (zh) | 2012-08-16 | 2015-08-26 | 孟加拉朱特研究所 | 来自菜豆壳球孢菌的纤维素和/或半纤维素降解酶及其用途 |
| US10253325B2 (en) | 2012-12-19 | 2019-04-09 | Boston Medical Center Corporation | Methods for elevating fat/oil content in plants |
| US9665694B2 (en) * | 2013-01-31 | 2017-05-30 | Codexis, Inc. | Methods, systems, and software for identifying bio-molecules with interacting components |
| GB201308828D0 (en) | 2013-03-12 | 2013-07-03 | Verenium Corp | Phytase |
| AU2014236162A1 (en) | 2013-03-14 | 2015-09-17 | Arzeda Corp. | Compositions having dicamba decarboxylase activity and methods of use |
| BR112015023272A2 (pt) | 2013-03-14 | 2017-07-18 | Pioneer Hi Bred Int | célula vegetal, planta, explante vegetal, semente transgênica, método para produzir uma célula vegetal tendo um polinucleotídeo heterólogo que codifica um polipeptídeo tendo atividade de dicamba descarboxilase, método para controlar plantas daninhas em um campo contendo uma cultura e método para controlar plantas daninhas em um campo contendo uma cultura |
| GB201308843D0 (en) | 2013-03-14 | 2013-07-03 | Verenium Corp | Phytase formulation |
| EP3027762A4 (en) | 2013-07-25 | 2017-06-28 | BASF Enzymes LLC | Phytase |
| EP3447493B1 (en) | 2014-01-07 | 2020-05-13 | Bioatla, LLC | Proteins targeting orthologs |
| US20180291413A1 (en) | 2015-10-06 | 2018-10-11 | Thermo Fisher Scientific Geneart Gmbh | Devices and methods for producing nucleic acids and proteins |
| US11291221B2 (en) | 2015-10-30 | 2022-04-05 | Beth Israel Deaconess Medical Center, Inc. | Methods for determination of bioactivity, quantity, removal, or inactivation of cereal amylase trypsin inhibitors in cereals, flours, plants, and complex foods |
| KR20190129032A (ko) | 2016-12-28 | 2019-11-19 | 인벡스, 인크. | 인플루엔자 백신 |
| MX2020004318A (es) | 2017-10-25 | 2020-08-13 | Basf Se | Enzimas beta-amilasa. |
| EP3728620A4 (en) * | 2017-12-20 | 2021-11-03 | Basf Se | GENE SITE SATURATION MUTAGENESIS (GSSM) PROCESS |
| US11732250B2 (en) | 2018-04-26 | 2023-08-22 | Basf Se | Lipase enzymes |
| WO2019211143A1 (en) | 2018-05-03 | 2019-11-07 | Basf Se | Amylase enzymes |
| CN112384616B (zh) | 2018-05-29 | 2024-09-03 | 巴斯夫欧洲公司 | 淀粉酶 |
| WO2019241216A1 (en) | 2018-06-14 | 2019-12-19 | Bioatla, Llc | Multi-specific antibody constructs |
| US12460221B2 (en) | 2018-09-07 | 2025-11-04 | Basf Plant Science Company Gmbh | Method for the production of high levels of PUFA in plants |
| EP3847264A1 (en) | 2018-09-07 | 2021-07-14 | Basf Plant Science Company GmbH | Improved method for the production of high levels of pufa in plants |
| CA3110656A1 (en) | 2018-09-07 | 2020-03-12 | Basf Plant Science Company Gmbh | Improved method for the production of high levels of pufa in plants |
| US20220186200A1 (en) | 2019-03-11 | 2022-06-16 | Basf Se | Amylases and methods for making and using them |
| CA3176520A1 (en) | 2019-04-23 | 2020-10-29 | Basf Se | Beta-amylase variants |
| US20230041211A1 (en) | 2019-12-20 | 2023-02-09 | Basf Se | Decreasing toxicity of terpenes and increasing the production potential in micro-organisms |
| BR112022024475A2 (pt) | 2020-06-04 | 2022-12-27 | Isobionics B V | Beta santaleno sintase sintética, ácido nucleico sintético, cassete de expressão, método para produzir uma composição, célula hospedeira não humana, composição, e, uso de qualquer uma das santaleno sintases sintéticas |
| EP4015626A1 (en) | 2020-12-18 | 2022-06-22 | Isobionics B.V. | Enzymes and methods for fermentative production of monoterpene esters |
| JP2024528957A (ja) | 2021-08-02 | 2024-08-01 | ビーエーエスエフ ソシエタス・ヨーロピア | イオニリデンエタンシンターゼによる新規な芳香化合物の生成 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959312A (en) | 1985-05-31 | 1990-09-25 | The University Of Tennessee Research Corporation | Full spectrum mutagenesis |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| EP1361273A3 (en) | 1992-11-24 | 2004-02-11 | G.D. Searle & Co. | Interleukin-3 (IL-3) multiple mutation polypeptides |
| CA2173329C (en) * | 1993-10-08 | 2011-07-12 | Henrik Bisgard-Frantzen | Amylase variants |
| US6187579B1 (en) | 1993-10-28 | 2001-02-13 | Carlsberg A/S | Customized proteases |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| US5389537A (en) | 1994-01-21 | 1995-02-14 | Wisconsin Alumni Research Foundation | Nuclease having altered specificity |
| EP0777748A1 (en) | 1994-08-18 | 1997-06-11 | Cytogen Corporation | Peptide librairies as a source of syngenes |
| DE69526665T2 (de) | 1994-09-21 | 2002-11-21 | Cytogen Corp., Princeton | Antigen bindende peptide (abtides) aus peptidbibliotheken |
| US5885577A (en) | 1994-09-21 | 1999-03-23 | Cytogen Corporation | Antigen binding peptides (abtides) from peptide libraries |
| WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
| US5789166A (en) | 1995-12-08 | 1998-08-04 | Stratagene | Circular site-directed mutagenesis |
| US5885827A (en) | 1996-01-23 | 1999-03-23 | The Regents Of The Universtiy Of California | Eukaryotic high rate mutagenesis system |
| KR100816621B1 (ko) | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| NZ500284A (en) | 1997-04-18 | 2001-09-28 | Biogen Inc | Type II TGF-beta receptor fusion proteins |
| AU7171098A (en) | 1997-05-01 | 1998-11-24 | Board Of Regents, The University Of Texas System | Directed evolution of enzymes and antibodies |
| EP1032683B1 (en) * | 1997-11-17 | 2005-02-02 | Novozymes Biotech, Inc. | Polypeptides having 5-aminolevulinic acid synthase activity and nucleic acids encoding same |
| AU755387B2 (en) * | 1997-12-16 | 2002-12-12 | Japan Tobacco Inc. | Polypeptides having aminopeptidase activity and nucleic acids encoding same |
| JP2002508971A (ja) | 1998-01-15 | 2002-03-26 | アリアド・ジーン・セラピューティクス・インコーポレーテッド | 多量体キメラ蛋白質を使用する生物学的イベントの調節 |
-
1999
- 1999-02-04 US US09/246,178 patent/US6171820B1/en not_active Expired - Lifetime
-
2000
- 2000-02-04 CA CA002325351A patent/CA2325351C/en not_active Expired - Fee Related
- 2000-02-04 JP JP2000597406A patent/JP2003524392A/ja active Pending
- 2000-02-04 AU AU34839/00A patent/AU3483900A/en not_active Abandoned
- 2000-02-04 WO PCT/US2000/003086 patent/WO2000046344A2/en not_active Ceased
-
2005
- 2005-03-18 JP JP2005080273A patent/JP2005245453A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000046344A2 (en) | 2000-08-10 |
| JP2003524392A (ja) | 2003-08-19 |
| US6171820B1 (en) | 2001-01-09 |
| JP2005245453A (ja) | 2005-09-15 |
| WO2000046344A3 (en) | 2000-12-28 |
| CA2325351A1 (en) | 2000-08-10 |
| CA2325351C (en) | 2005-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6479258B1 (en) | Non-stochastic generation of genetic vaccines | |
| US6713279B1 (en) | Non-stochastic generation of genetic vaccines and enzymes | |
| EP2397549A2 (en) | Non-stochastic generation of genetic vaccines and enzymes | |
| US20110165627A1 (en) | Gene site saturation mutagenesis | |
| AU3483900A (en) | Non-stochastic generation of genetic vaccines and enzymes | |
| US20030219752A1 (en) | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof | |
| EP1421203A2 (en) | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof | |
| US6635449B2 (en) | Exonuclease-mediated nucleic acid reassembly in directed evolution | |
| US6358709B1 (en) | End selection in directed evolution | |
| US6773900B2 (en) | End selection in directed evolution | |
| WO2000058517A1 (en) | Exonuclease-mediated nucleic acid reassembly in directed evolution | |
| AU3879300A (en) | End selection in directed evolution | |
| US6939689B2 (en) | Exonuclease-mediated nucleic acid reassembly in directed evolution | |
| AU2005201125B2 (en) | Non-stochastic generation of genetic vaccines and enzymes | |
| AU2009212959B2 (en) | Synthetic ligation reassembly in directed evolution | |
| EP1073710A2 (en) | Non-stochastic generation of genetic vaccines and enzymes | |
| AU2002318140A1 (en) | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof | |
| AU2005203719A1 (en) | End selection in directed evolution |